Chronification of migraine headache is one of the major issues to resolve urgently. The prevalence of chronic migraine is close to 2%, and the chronification occurs in approximately 2.5% of episodic cases annually.The pathophysiology of transformation from episodic to chronic migraine is still unclear. It is considered that there are several risk factors for migraine chronification; 1) non-modifiable: age, low education/socioeconomic status, and head injury, 2) modifiable: attack frequency, obesity, medication overuse, stressful life events, caffeine overuse, snoring, and other pain syndrome, 3) currently putative: allodynia, proinflammatory states, prothrombotic states, and specific genes.There were a few clinical reports concerning to the migraine transformation from abroad, but few data from Japan. The prevalence of chronic daily headache in our headache clinic in Japan was 20-30%. The medication overuse headache was the most prevalent form in the highest attack frequency (>15 days/month) grope. Discontinuation of overused medication and administration of prophylactic medication were effective, and 40% of followed cases kept out of MOH at two years later.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.5692/clinicalneurol.53.1223 | DOI Listing |
J Headache Pain
November 2024
Headache Center, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Objective: To delineate the structural connectome alterations in patients with chronic migraine (CM), episodic migraine (EM), and healthy controls (HCs).
Background: The pathogenesis of migraine chronification remains elusive, with structural brain network changes potentially playing a key role. However, there is a paucity of research employing graph theory analysis to explore changes in the whole brain structural networks in patients with CM and EM.
Neurologia (Engl Ed)
June 2023
Servicio de Neurología, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain. Electronic address:
J Clin Med
October 2024
Department of Neurology, Endeavor Health, Evanston, IL 60201, USA.
: Genome-wide association studies (GWASs) demonstrate a complex genetic landscape for migraine risk. Migraine polygenic risk scores (PRSs) developed from GWAS data may have utility for predicting disease course. We analyzed the strength of association between an integrative migraine PRS and age at onset and chronification.
View Article and Find Full Text PDFHeadache
November 2024
Department of Neurology, Danish Headache Center, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
Objective: To evaluate long-term reductions in acute headache medication (AHM) use with eptinezumab versus placebo in patients with prior preventive migraine treatment failures and medication overuse (MO).
Background: Preventive migraine treatment is recommended for patients for whom AHMs have failed and for those who are using excessive amounts of AHM. MO may worsen headache and migraine symptoms in people with migraine; it is a risk factor for disease chronification and/or MO headache.
Drug Deliv Transl Res
November 2024
Department of Pharmacology and Therapeutics, Faculty of Pharmacy, Pharos University in Alexandria, Alexandria, 21648, Egypt.
Conventional zolmitriptan (ZOL) has limited oral bioavailability, many adverse effects, and poor membrane penetrability that negatively influences its accessibility to its 5-HT receptor binding pocket, located transmemberanous. This work aimed at preparing transdermal ZOL-nanoformulation (niosomes) to surpass these limitations and to explore novel antimigraine mechanisms for ZOL via modulation of the epigenetically-altered chronification genes (RAMP-1, NPTX-2) or microRNAs and affecting the endocannabinoid CB-1/MAPK pathway. The prepared ZOL niosomes (F) exhibited %EE of 57.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!